Novartis’ Fabhalta (Iptacopan) Receives FDA Priority Review for IgA Nephropathy (IgAN) Treatment
Novartis, Fabhalta, Iptacopan, IgA Nephropathy (IgAN), FDA Priority Review, Phase 3 Data
Ultragenyx’s GTX-102 Shows Promising Results in Mid-Stage Angelman Syndrome Study, Pivotal Study on the Horizon
Ultragenyx, GTX-102, Angelman Syndrome, Mid-Stage Study, Pivotal Study, Antisense Oligonucleotide, Cognitive Improvement, Behavioral Improvement, Sleep Improvement, Gross Motor Improvement
Regeneron Launches $500M Venture Fund Led by Former Executives
Regeneron/ venture fund/ $500 million/ biotech/ former executives/ innovation/ investment/ 2024.
Marinus Pharmaceuticals Shares Plummet Due to Seizure Treatment Trial Setbacks
Marinus/ Pharmaceuticals/ seizure treatment/ trial failure/ high expectations/ shares plummet
Neumora’s Schizophrenia Drug Study Halted by FDA Due to Preclinical Safety Signals
Neumora Therapeutics, Schizophrenia drug study, NMRA-266, Preclinical safety signals, Convulsions in rabbits, Clinical hold, Phase I trial
Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers
Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements
The Transformative Future of Specialist Distribution: Adaptive Strategies and Technological Innovations
Specialist Distribution, Future Trends, Adaptive Strategies, Technological Innovations, Automation, Artificial Intelligence, Last-Mile Solutions, Virtual Distribution, Data Integration, Global Expansion, Smart Distribution Centers
Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits
Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia
Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech
Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence
Regeneron Unveils $500M Biotech-Focused Venture Capital Fund
Regeneron, Venture Capital Fund, Biotech, $500 million